The Board of Directors of Aarti Pharmalabs approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. The Board also declared an Interim Dividend of ₹1.50 (30%) per Equity Share of ₹5/- each for FY 2025-26, with February 16, 2026 set as the Record Date. Standalone Net Profit for Q3 FY26 stood at ₹4,384.46 lakhs.
Quarterly Financial Outcomes (Q3 FY26)
Aarti Pharmalabs Limited announced the outcome of its Board meeting held on Monday, February 09, 2026. The Board inter-alia approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2025, along with the Auditor’s Report.
Standalone Financial Highlights (3 Months Ended Dec 31, 2025)
The key figures for the standalone operations during the third quarter of the current financial year are as follows:
- Total Income: ₹42,488.16 lakhs, compared to ₹48,288.30 lakhs in the previous corresponding quarter (Q3 FY25 Audited).
- Profit Before Tax: ₹5,858.10 lakhs.
- Net Profit for the period: ₹4,384.46 lakhs.
- Earnings Per Share (Basic): ₹4.84.
Consolidated Financial Highlights (3 Months Ended Dec 31, 2025)
The consolidated performance for the quarter ending December 31, 2025, showed the following:
- Total Income: ₹43,190.15 lakhs.
- Profit Before Tax (after JV share): ₹6,286.88 lakhs.
- Net Profit for the period attributable to Owners: ₹4,795.56 lakhs.
- Earnings Per Share (Basic): ₹5.29.
Interim Dividend Declaration
In a significant move for shareholders, the Board declared an Interim Dividend of ₹1.50/- per Equity Share, representing 30% of the face value of ₹5/- each, for the Financial Year 2025-26.
To facilitate this payment, Monday, February 16, 2026, has been fixed as the ‘Record Date’, pursuant to the applicable regulations.
Accounting and Operational Notes
The financial results noted a significant exceptional item: an incremental provision of ₹279.49 lakhs made to account for the impact of newly notified labor codes by the Government of India.
Furthermore, note 3 highlights that revenue of ₹4,935 lakhs related to goods shipped but still in transit as of December 31, 2025, has been excluded from the current period results and will be recognized in the subsequent quarter (Q4 FY26) upon reaching the destination.
The consolidated results incorporate the performance of Subsidiaries (Aarti USA Inc and Aarti Pharmachem Ltd.) and the joint venture, Ganesh Polychem Limited, which became a joint venture effective April 1, 2025.
Source: BSE
